Adragos Hub

When an injectable solution is administered, it bypasses the patient’s normal protective barriers. Skin and the digestive system no longer act as filters. At that point, the primary packaging becomes the barrier. That is the starting point for any sterility […]

● Live Webinar  ·  25 June 2026 De-Risking Sterile Fill-Finish from Clinical to Commercial How expanded CDMO capabilities, lyophilisation expertise and a flexible facility network help accelerate sterile product success. Sterile product development and manufacturing can be complex. Scale-up, lyophilisation, […]

A Step-by-Step Guide for CMC and Technical Operations Leaders Commercial technology transfer of sterile injectables to a European Contract Development and Manufacturing Organisation involves seven defined stages: CDMO selection and technical due diligence; a formal technology transfer plan and risk […]

Contents Phase 1: Define Your Programme Requirements Phase 2: Due Diligence and Capability Screening Phase 3: Site Qualification and GMP Auditing Phase 4: Assemble the Technical Data Package Phase 5: Stakeholder Governance and Programme Management Phase 6: Technology Transfer from […]

Onboarding a sterile injectable fill-finish Contract Development and Manufacturing Organisation (CDMO) involves eight structured steps: defining your manufacturing requirements, establishing selection criteria, conducting a formal technical audit, completing a feasibility assessment, compiling Chemistry, Manufacturing and Controls (CMC) documentation for European […]

To audit a sterile fill-finish Contract Development and Manufacturing Organisation (CDMO) effectively in 2026, assess nine core areas: quality management systems, contamination control strategy, facility and equipment qualification, technology transfer capability, data integrity controls, analytical and stability services, supply chain […]